Praveen Tipirneni, Morphic CEO
February 24, 2022 10:35 AM EST
R&D

Ab­b­Vie cuts away part of its part­ner­ship with Mor­phic on in­te­grin re­search for fi­bro­sis

Kyle Blankenship

De­spite a qui­et few years, Mor­phic Ther­a­peu­tic was once a buzzy biotech look­ing to move in­te­grin re­search in­to the next gen­er­a­tion. Now, a drug gi­ant …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times